Home

Mathai Mammen

CIK 1421050 · EVP, Pharm, R&D · last filed 2024-06-13

Mathai Mammen is an EVP, Pharm, R&D who has filed 64 SEC Form 4 insider transactions across 4 companies since 2008. The most recent filing, for TXG, was dated Jun 13, 2024. Across all open-market trades the lifetime net is −$4.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $29.3M across reported positions. 50 SEC filings were submitted jointly with Innoviva, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$29.30M

Companies

4

Total Filings

64

Lifetime Open-Market Net

-$4.70M

Filer Profile

Reported Address
THERAVANCE,INC.
901 GATEWAY BLVD.
SOUTH SAN FRANCISCO, CA 94080
Related Filers
Innoviva, Inc. — 50 joint filings, latest 2014-08-22
& JOHNSON JOHNSON — 3 joint filings, latest 2022-02-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
TXG Director 180,259 $68.59 $12.36M -$1.74M 7 2024-06-13
JNJ EVP, Pharm, R&D 45,300 $265.58 $12.03M $0 2 2022-02-17
TBPH SVP, Research & Development 288,111 $17.01 $4.90M $0 10 2016-03-17
Innoviva, Inc. (THRX) Delisted SVP, Research & Early Clin Dev 334,040 $4.06 $1.36M -$2.96M 44 2014-08-22

Recent Filings

64 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-06-13 TXG Grant (A) +8,649 $0 EDGAR
2023-06-16 TXG Grant (A) +1,865 $0 EDGAR
2023-05-15 TXG Mixed +167,000 -$1.51M EDGAR
2023-05-11 TXG Notice (144) −33,000 -$1.79M EDGAR
2022-06-17 TXG Grant (A) +2,120 $0 EDGAR
2022-02-17 JNJ Mixed +4,374 -$558.4K EDGAR
2022-02-15 JNJ Mixed +5,083 -$394.3K EDGAR
2021-06-15 TXG Grant (A) +625 $0 EDGAR
2020-06-17 TXG Grant (A) — $0 EDGAR
2019-09-16 TXG Other (J) — $0 EDGAR
Showing 1–10 of 64
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.